Níveis séricos de NT pro-BNP: relação com função sistólica e diastólica nas miocardiopatias e pericardiopatias

Mady, Charles; Fernandes, Fábio; Arteaga, Edmundo; Ramires, Felix José Alvarez; Buck, Paula; Salemi, Vera Maria Cury; Ianni, Bárbara Maria; Nastari, Luciano; Dias, Ricardo Ribeiro

doi:10.1590/s0066-782x2008001300008

Cited by 13 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain Natriuretic Peptide, NTproBNP and troponin, all known cardiac biomarkers, showed strong associations with dilated cardiomyopathy in both infected and uninfected participants [14] . Our results are consistent with previous studies of these markers in CCM [18] – [20] , [31] . Perhaps because of its long half-life, NTproBNP showed the strongest association with cardiac disease [24] .…”

Section: Discussionsupporting

confidence: 94%

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

et al. 2014

View full text Add to dashboard Cite

BackgroundTwenty to thirty percent of persons with Trypanosoma cruzi infection eventually develop cardiomyopathy. If an early indicator were to be identified and validated in longitudinal studies, this could enable treatment to be prioritized for those at highest risk. We evaluated cardiac and extracellular matrix remodeling markers across cardiac stages in T. cruzi infected (Tc+) and uninfected (Tc−) individuals.MethodsParticipants were recruited in a public hospital in Santa Cruz, Bolivia and assigned cardiac severity stages by electrocardiogram and echocardiogram. BNP, NTproBNP, CKMB, troponin I, MMP-2, MMP-9, TIMP-1, TIMP-2, TGFb1, and TGFb2 were measured in specimens from 265 individuals using multiplex bead systems. Biomarker levels were compared between Tc+ and Tc− groups, and across cardiac stages. Receivers operating characteristic (ROC) curves were created; for markers with area under curve>0.60, logistic regression was performed.ResultsAnalyses stratified by cardiac stage showed no significant differences in biomarker levels by Tc infection status. Among Tc+ individuals, those with cardiac insufficiency had higher levels of BNP, NTproBNP, troponin I, MMP-2, TIMP-1, and TIMP-2 than those with normal ejection fraction and left ventricular diameter. No individual marker distinguished between the two earliest Tc+ stages, but in ROC-based analyses, MMP-2/MMP-9 ratio was significantly higher in those with than those without ECG abnormalities.ConclusionsBNP, NTproBNP, troponin I, MMP-2, TIMP-1, and TIMP-2 levels rose with increasing severity stage but did not distinguish between Chagas cardiomyopathy and other cardiomyopathies. Among Tc+ individuals without cardiac insufficiency, only the MMP-2/MMP-9 ratio differed between those with and without ECG changes.

show abstract

Section: Discussionsupporting

confidence: 94%

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Results from these studies are contradictory, indicating that serum BNP levels are similar in T. cruzi-infected and uninfected individuals [51]. Other natriuretic peptides (NT-proBNP [52][53][54], BNP [55][56][57] and atrial natriuretic peptide [46,49]) and troponin I and T [58] have been proposed to differentially diagnosis late stages of CD.…”

Section: Biochemical and Metabolic Moleculesmentioning

confidence: 99%

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review

Pinazo

Thomas

Búa

et al. 2014

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

The most neglected aspects of Chagas disease (CD) have been patient care and treatment. Despite recent progress in the development of potentially improved drugs, there is no consensus among different research groups on the lack of therapeutic response markers to evaluate efficacy of newly proposed drugs early after treatment. A systematic review of current evidence regarding molecules which are potential biomarkers for therapeutic response has been conducted using quality assessment and target responses as primary criteria. The review provides a panorama of the cumulative evidence and specific needs for development of a battery of complementary biomarkers which together fulfill ideal or acceptable criteria to evaluate early responses to treatment for chronic CD. There are several marker candidates which together may fulfill acceptable criteria to indicate the efficacy of a trypanocidal treatment. Data from ongoing studies are considered essential to improve assessment of existing markers and to identify those for early follow-up of treated patients.

show abstract

“…A small recent series has shown that BNP levels are markedly high in patients with restrictive cardiomyopathy and NYHA functional class III or IV, while, in patients with similar clinical findings and constrictive pericarditis, BNP levels are much lower 30 . However, BNP levels vary with the different etiologies of restrictive cardiomyopathy and constrictive pericarditis 31 , requiring new studies to assess whether the BNP/proBNP ratio plays a potential role in that scenario and in variations, such as associated renal disease.…”

Section: Introductionmentioning

confidence: 99%

“…The measurement of NT-proBNP as a biomarker has been assessed in some studies, which have shown its increased serum levels in endomyocardial fibrosis as compared with a normal control group 32 .…”

Section: Introductionmentioning

confidence: 99%

“…Measuring BNP or NT-proBNP can be useful for differential diagnosis and follow-up. The increase of those markers in patients with constrictive pericarditis, as well as their correlation with echocardiographic rates that assess diastolic function, has been well defined 46 . In the post-pericardiectomy follow-up of patients with constrictive pericarditis, BNP can be used to assess the results and diastolic function improvement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in Cardiology - Part 1 - In Heart Failure and Specific Cardiomyopathies

2014

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Cardiovascular diseases are the leading causes of mortality and morbidity in Brazil. The primary and secondary preventions of those diseases are a priority for the health system and require multiple approaches to increase their effectiveness. Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to aid in treatment and prognosis determination. This review aims to highlight the importance of biomarkers in clinical cardiology practice, and to raise relevant points of their use and the promises for the coming years. This document was divided into two parts, and this first one discusses the use of biomarkers in specific cardiomyopathies and heart failure.

show abstract

Níveis séricos de NT pro-BNP: relação com função sistólica e diastólica nas miocardiopatias e pericardiopatias

Cited by 13 publications

References 18 publications

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review

Biomarkers in Cardiology - Part 1 - In Heart Failure and Specific Cardiomyopathies

Contact Info

Product

Resources

About